Being the downstream effectors in the inflammasome pathway, higher expression of GSDMD correlates with the pathophysiology of lung cancer, resulting in increased tumor size, advanced stages, and reduced survival rates in LUAD and LUSC patients. The gene discussed is GSDMD; the disease is lung carcinoma.